This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Agios' (AGIO) only marketed drug Idhifa that looks effective to cure patients with relapsed or refractory acute myeloid leukemia might drive the company's earnings in Q3.
Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View
by Zacks Equity Research
Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.
Is Celgene (CELG) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.
Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss with revenues marginally lagging estimates. However, the top line improves year over year, thanks to reimbursement received from Celgene.
Agios (AGIO) Q2 Loss Wider than Expected; Sales Miss
by Zacks Equity Research
Agios (AGIO) posted wider-than-expected loss in the second quarter of 2017. Revenues also came below expectations. However, revenues increased significantly year-over-year.
4 Medical Product Stocks Likely to Top Q2 Earnings Estimates
by Zacks Equity Research
There are some powerful long-term tailwinds in the medical space.
Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More
by Zacks Equity Research
Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.
Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Expenses Hit Envision Healthcare (EVHC) Q2 Earnings?
by Zacks Equity Research
Envision Healthcare's (EVHC) second-quarter earnings may suffer from high operating cost and low revenues from the ambulatory service unit.
Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise over 5% on the day.
Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote
by Arpita Dutt
Companies like Gilead (GILD) topped expectations in the second quarter while Dynavax shot up on a positive FDA advisory panel vote.
Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene Corporation (CELG) beat earnings and revenue estimates in the second quarter and upped view.
What's in Store for Agios Pharma (AGIO) in Q2 Earnings?
by Zacks Equity Research
Encouraging performance of Agios' (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2.
Is Celgene (CELG) Poised For a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.
Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China
by Zacks Equity Research
Celgene Corporation (CELG) recently entered into a strategic collaboration with China based-BeiGene, Ltd. (BGNE).
Agios/Celgene's Leukemia Candidate Positive in Phase I/II
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) has announced a positive efficacy and safety data from the ongoing phase I/II study on experimental candidate IDHIFA (enasidenib) at an oral session at the European Hematology Association (EHA).
Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial
by Zacks Equity Research
Celgene Corporation (CELG) announced results from the phase II trial, SLE-001 which evaluated lupus candidate, CC-220, at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid.
Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Agios (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celgene and Agios Announce Data on Idhifa for Leukemia
by Zacks Equity Research
Celgene Corporation (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced new efficacy and safety data on experimental candidate Idhifa (enasidenib).
Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.
Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents.
Agios (AGIO) Q1 Loss Narrower than Expected; Sales Down Y/Y
by Zacks Equity Research
Agios posted narrower-than-expected loss in the first quarter of 2017. Our consensus called for a loss of $1.79 per share, and the company reported a loss of $1.56.
Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.
Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View
by Zacks Equity Research
Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.
Key Factors to Look Out for in Celgene's (CELG) Q1 Results
by Arpita Dutt
Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.